Page 293 - Read Online

Pasini et al. Hepatoma Res 2020;6:26 I http://dx.doi.org/10.20517/2394-5079.2019.47 Page 9 of 9

61. Llovet JM, Real MI, Montaña X, Planas R, Coll S, et al.; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation
versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet
2002;359:1734-9.
62. Jin YJ, Lee JW, Lee OH, Chung HJ, Kim YS, et al. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent
hepatocellular carcinoma with or without microvascular invasion. J Gastroenterol Hepatol 2014;29:1056-64.
63. Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, et al.; Liver Cancer Study Group of Japan. Overall survival after transarterial lipiodol
infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J
Roentgenol 2010;194:830-7.
64. Erridge S, Pucher PH, Markar SR, Malietzis G, Athanasiou T, et al. Meta-analysis of determinants of survival following treatment of
recurrent hepatocellular carcinoma. Br J Surg 2017;104:1433-42.
65. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular
carcinoma. N Engl J Med 2008;359:378-90.
66. Bruix J, Qin S, Merle P, Granito A, Huang YH, et al.; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma
who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
67. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable
hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73.
68. Kumar M, Panda D. Role of supportive care for terminal stage hepatocellular carcinoma. J Clin Exp Hepatol 2014;4:S130-9.